초록 ▼

The invention relates to drug delivery systems comprising a water-soluble polymer matrix and a bioactive agent entrained therein, said water soluble polymer matrix containing at least 50 wt. % of polyoxazoline having a molar mass of at least 5 40,000 g/mol. The drug delivery systems of the present i

The invention relates to drug delivery systems comprising a water-soluble polymer matrix and a bioactive agent entrained therein, said water soluble polymer matrix containing at least 50 wt. % of polyoxazoline having a molar mass of at least 5 40,000 g/mol. The drug delivery systems of the present invention offer the advantage that the bioactive agent is readily released when the drug delivery system is contacted with water. The drug delivery system can be in the form of a solid dispersion, a mucoadhesive sheet, a tablet, a powder, a capsule.

대표청구항 ▼

1. A drug delivery system comprising a solid dispersion of an amorphous cannabinoid in a water-soluble polymer matrix, said water-soluble polymer matrix comprising at least 50 wt. % of polyoxazoline having a molar mass of at least 40,000 g/mol and said cannabinoid being contained in the solid disper

1. A drug delivery system comprising a solid dispersion of an amorphous cannabinoid in a water-soluble polymer matrix, said water-soluble polymer matrix comprising at least 50 wt. % of polyoxazoline having a molar mass of at least 40,000 g/mol and said cannabinoid being contained in the solid dispersion in a concentration of at least 0.5% by weight of the water-soluble polymer matrix. 2. The drug delivery system according to claim 1, wherein the solid dispersion is a solid solution. 3. The drug delivery system according to claim 2, wherein the solid solution has a glass transition temperature (Tg) of at least 45° C. 4. The drug delivery system according to claim 2, wherein the cannabinoid has a Tg of less than 40° C. 5. The drug delivery system according to claim 4, wherein the cannabinoid has a Tg of −30° C. to less than 40° C. and wherein said cannabinoid is contained in the drug delivery system in a concentration of 0.5-30% by weight of the water-soluble polymer matrix. 6. The drug delivery system according to claim 1, wherein the amorphous cannabinoid in the form of nanoparticles having a volume weighted average diameter of less than 100 nm. 7. The drug delivery system according to claim 1, wherein the polyoxazoline has a molar mass of at least 80,000 g/mol. 8. The drug delivery system according to claim 7, wherein the polyoxazoline has a molar mass of at least 150,000 g/mol. 9. The drug delivery system according to claim 1, wherein the polyoxazoline is a poly(N-acylalkylenimine) having repeating units comprising the formula (CH2)mNCOR1; R1 being selected from H, C1-22 alkyl, cycloalkyl, aralkyl, aryl; and m being 2 or 3. 10. The drug delivery system according to claim 1, wherein the water-soluble polymer matrix represents 20-99.999 wt. % of the drug delivery system. 11. The drug delivery system according to claim 1, wherein the drug delivery system is in the form of a powder, a tablet, a capsule or a mucoadhesive sheet. 12. The drug delivery system according to claim 1, wherein the drug delivery system is a powder having a mass weighted average diameter of 0.1-250 μm. 13. The drug delivery system according to claim 1, wherein the drug delivery system comprises a powder having a mass weighted average diameter of 0.1-250 μm in the form of an oral dosage unit selected from a tablet and a capsule. 14. The drug delivery system according to claim 1, wherein the drug delivery system is a mucoadhesive sheet comprising at least 20 wt. % of a water-soluble polymer matrix in the form of thin film. 15. A method of preparing a drug delivery system according to claim 1, comprising: (a) combining a solvent, the polyoxazoline and the cannabinoid to form a solution of the polyoxazoline in the solvent, said solution comprising the cannabinoid in dispersed and/or dissolved from; and(b) removing the solvent from the solution. 16. A method of preparing a drug delivery system according to claim 1, comprising: (a) combining the cannabinoid and the polyoxazoline to form a mixture having a temperature above the glass transition temperature of said mixture; and(b) cooling the mixture to a temperature below said glass transition temperature.